Midostaurin

In this article, we will discuss Midostaurin (Dosage Overview). So, let’s get started.

Indications

Acute Myeloid Leukemia

Midostaurin is indicated, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation
chemotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) who are FLT3 mutation-positive, as detected by a FDA approved test.

Limitations of Use

Midostaurin is not indicated as a single-agent induction therapy for the treatment of patients with AML.

Systemic Mastocytosis

Midostaurin is indicated for the treatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL).

Dosage

Patient Selection

Select patients for the treatment of AML with Midostaurin based on the presence of FLT3 mutation positivity.

Recommended Dosage in Acute Myeloid Leukemia

The recommended dose of Midostaurin for patients with acute myeloid leukemia is 50 mg orally twice daily with food on Days 8 to 21 of each cycle of induction with cytarabine and daunorubicin and on Days 8 to 21 of each cycle of consolidation with high-dose cytarabine.

Recommended Dosage in ASM, SM-AHN, and MCL

The recommended dose of Midostaurin for patients with ASM, SM-AHN, and MCL is 100 mg orally twice daily with food. Continue treatment until disease progression or unacceptable toxicity occurs.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.